Biotech Values

[DewDiligence]

NVS acquires (private) Encore Vision for undisclosed price:

https://t.co/pAFmIt0ci6

Novartis announced today that it has entered into a definitive agreement for the acquisition of Encore Vision, Inc., a privately-held company in Fort Worth, Texas, USA, focused on the development of a novel treatment in presbyopia.

This acquisition would add a first-in-class disease modifying topical treatment for presbyopia to the Novartis ophthalmology pipeline, providing a potentially disruptive innovation to patients in a new therapeutic area of high unmet need and high prevalence.

A safe and effective topical treatment for presbyopia would indeed be a big deal, but the technical hurdles are high.